, China
37 views

Chinese vaccines remain vital in developing nations despite criticisms

Developing nations face inadequate supply as developed nations stockpiled vaccines from top manufacturers.

Amidst the global demand for COVID-19 vaccines and the supply-demand gaps, Chinese vaccines remain crucial for developing nations’ vaccination programs despite criticisms regarding real-world data on the vaccines’ efficacy, according to a report from GlobalData.

The country has so far provided COVID-19 vaccine aid to more than 50 developing nations. However, Chinese vaccines were criticized for lack of peer-reviewed data over their efficacy in Phase III trials.

GlobalData’s Pharma Analyst Prashant Khadayate commented that Chinese vaccines have shown varied efficacy rates across countries in clinical trial settings from over 50% to 79%, and real-world data appeared to validate the data observed in a clinical trial setting.

“However, low efficacy observed in real-world data will not hurt the future uptake as developed nations have already stockpiled large quantities of COVID-19 vaccines from leading manufactures... leading to inadequate supply for developing nations,” Khadayate said.

Amongst the top 15 economies, Brazil and Mexico are the only two countries that have approved Chinese vaccines. GlobalData noted that most of the COVID-19 vaccines being supplied to developing countries are by companies based out of Russia, China, and India.

However, India is currently struggling with a severe second wave of COVID-19 and the focus is shifting towards vaccinating its own population and less towards supplying other nations.

As a result, the WHO-backed COVAX initiative has slashed the number of vaccines to be delivered by end-May from about 240 million doses to 145 million. The initiative was also only able to supply 41 million doses so far of its two billion doses promised by the end-2021.

“Chinese vaccine manufacturers are already playing a key role in supplying vaccines to developing countries. The supply of COVID-19 vaccines from China are expected to improve further and be of increased importance amid the supply issues within India in the wake of second wave of COVID-19,” Khadayate said.
 

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Get Health Care Asia Magazine in your inbox

Find out who won at this year's Healthcare Asia Awards and Healthcare Asia Pharma Awards 

The event was held via video conferencing that started last 15 April.

What investment opportunities await for India’s health-tech space?

Before the pandemic, the industry focussed on wearables, lifestyle-linked problems, and more.

Singapore’s Tan Tock Seng Hospital closes wards to visitors

Two patients and two staff were infected by COVID-19.

Hygeia Healthcare buys 100% stake in Etern Group for $268m

The acquisition indirectly holds 98% of Suzhou Yongding Hospital in Jiangsu.

How reach52 bridges the gap in healthcare with tech

The unique startup aims to connect to 250 million individuals across the globe by 2030.

He Health bags internet hospital license in China

The online platform offers services such as men’s health consultations.

Indonesia's telehealth platform Halodoc bags $80m in funding

The funds will be used to deepen its penetration in key healthcare verticals in Indonesia.

South Korea eases requirements for drug imports

Pharmaceutical companies could benefit from the government’s drive to reduce regulatory uncertainty.

Taiwan's novel pharma products hit by low reimbursement prices

The low rates are discouraging the launch of new innovative products, insiders say.

Japan's liver cancer surveillance program hailed as world's best

The country established the programme for early detection of HCC in the 1980s.